Cardiol Therapeutics 株価情報 (NASDAQ: CRDL)

最新ニュース Cardiol Therapeutics (NASDAQ:CRDL) 株価情報

Cardiol Therapeutics

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics Inc. - Class A Common Shares

Cardiol Therapeutics Inc

News

Management

OACC

Oaktree Acquisition Corp. III Life Sciences CFO Courtney Conigliaro Resigned On June 3, 2025;  Thomas Sweeney Named As New Chief Financial Officer Effective Immediately

BBAI

BigBear.ai Names Sean Ricker Interim Chief Financial Officer, Effective Immediately

Offerings

TIVC

Tivic Health Systems Inc Files For Resale Of 8.4M Shares Of Common Stock By Selling Stockholder

On June 6, 2025, Nektar Therapeutics (the "Company") filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Increase in Authorized Shares Amendment") with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company's common stock, par value $0.0001 (the "Common Stock"), from 300,000,000 shares to 390,000,000 shares. The Increase in Authorized Shares Amendment was previously approved by the Company's stockholders at the Annual Meeting of Stockholders held on May 23, 2025 and became effective upon its filing.
&nbsp;
A copy of the Increase in Authorized Shares Amendment is filed as Exhibit 3.1 hereto and is incorporated herein by reference.
&nbsp;
On June 6, 2025, the Company also filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the "Reverse Stock Split Amendment") with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company's Common Stock at a ratio of one-for-fifteen (the "Reverse Stock Split"). The Reverse Stock Split Amendment provides that the Reverse Stock Split will become effective as of 11:59 p.m. Eastern Time on June 8, 2025 (the "Effective Time"), at which time every fifteen shares of the Company's Common Stock issued and outstanding immediately prior to the Effective Time will be automatically combined into one share of Common Stock. No fractional shares of Common Stock will be issued as a result of the Reverse Stock Split. Instead, any fractional shares resulting from the Reverse Stock Split will be rounded up at the participant level with The Depository Trust Company, if such shares of Common Stock are held directly or rounded down to the nearest whole share of Common Stock, if such shares are subject to an award granted under the 2017 Amended and Restated Performance Incentive Plan.
&nbsp;
Trading of the Company's common stock on a split-adjusted basis will begin at market open on June 9, 2025 under the existing symbol "NKTR" and new CUSIP number 640268306. The Reverse Stock Split will not change the number of authorized shares of the Company's Common Stock, which will remain at 390,000,000 shares following effect of the Increase in Authorized Shares Amendment.
&nbsp;
A copy of the Reverse Stock Split Amendment is filed as Exhibit 3.2 hereto and is incorporated herein by reference.

Stock Split

NKTR

Nektar Therapeutics Files Amendments To Increase Authorized Common Stock From 300M To 390M Shares And Implement 1-For-15 Reverse Stock Split Effective June 8, 2025; Split-Adjusted Trading To Begin June 9, 2025

Guidance

PLCE

Children's Place Says Results Remain Under Pressure Due To Current Macroeconomic Environment;For Fiscal 2025, We Expect To See Continued Top-line Sales Pressures

BRZE

Braze Files For Resale Of $3.9M Shares Of Class A Common Stock By Selling Stockholders

NOTE

FiscalNote Holdings Files For Offering Of Up To 12.5M Class A Common Stock By Selling Stockholder

LVWR

Livewire Group Tralisa Maraj Resigns As CFO Effective July 11, 2025

<a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1190935/000119312525137029/d191650d424b5.htm" title="https://www.sec.gov/ix?doc=/Archives/edgar/data/1190935/000119312525137029/d191650d424b5.htm">https://www.sec.gov/ix?doc=/Archives/edgar/data/1190935/000119312525137029/d191650d424b5.htm</a>

Pimco Announces $1B Offering

General

Asbury Automotive Group Expects Herb Chambers Deal To Close By July 2025

IOTR

iOThree Receives Nasdaq Notice For Non-Compliance With $1.00 Bid Price Requirement

The Oncology Institute Files For Stock Shelf Of Up to $50M

CAPT

Captivision Receives Staff Determination Notice From Nasdaq

MOVE

CORRECTION: Movano Announced Its Nasdaq Notification Of Deficiency On May, 23

Children's Place (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLCE#NASDAQ">PLCE</a>) reported quarterly losses of $(1.52) per share which missed the analyst consensus estimate of $(0.51) by 198.04 percent. This is a 28.81 percent decrease over losses of $(1.18) per share from the same period last year. The company reported quarterly sales of $242.13 million which missed the analyst consensus estimate of $260.62 million by 7.10 percent. This is a 9.61 percent decrease over sales of $267.88 million the same period last year.

Earnings

Earnings Misses

Children's Place Q1 Adj. EPS $(1.52) Misses $(0.51) Estimate, Sales $242.13M Miss $260.62M Estimate

Somnigroup International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) has outperformed the market over the past 15 years by 2.71% on an annualized basis producing an average annual return of 14.7%. Currently, Somnigroup International has a market capitalization of $13.65 billion. 
Buying $100 In SGI: If an investor had bought $100 of SGI stock 15 years ago, it would be worth $796.47 today based on a price of $65.45 for SGI at the time of writing.
<h3>Somnigroup International's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749241823_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Somnigroup International 15 Years Ago Would Be Worth This Much Today

WIIM

Nuveen Insured California Premium Fund Ii

Northann shares are trading higher amid ongoing volatility. The company announced  that it is not aware of any new material developments or pending announcements concerning its business operations that may be contributing to the recent volatile market activity.

Lazydays Holdings, Inc. (NASDAQCM: GORV) ("Lazydays" or the "Company") announced today that it has closed on the asset sale and real estate sale of its Ft. Pierce, Florida location to General R.V. Center, Inc. ("General RV"). The companies expect to complete the remaining divestiture in Longmont, Colorado in the coming weeks.

Asset Sales

GORV

Lazydays Closes Sale Of Ft. Pierce, FL Assets And Real Estate To General RV, With Longmont, CO Divestiture Expected In Coming Weeks

BrightView Holdings Enters Underwriting Agreement For 11.6M Shares Of Common Stock

Broadway Technology Inc ("Gaokai"), a leading manufacturer of high-quality PET (polyethylene terephthalate) cups and lids through its operating subsidiary Zhejiang Gaokai New Materials Co., Ltd., announced the execution of an Agreement and Plan of Merger (the "Merger Agreement") for a business combination with Quartzsea Acquisition Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSEAU#NASDAQ">QSEAU</a>, QSEA, QSEAR))) ("Quartzsea"), a publicly traded special purpose acquisition company.
Upon consummation of the transaction contemplated by the Merger Agreement, (i) Quartzsea will be merged with and into Cuisine Universal Packaging Solution, a Cayman Islands exempted company and wholly owned subsidiary of Quartzsea ("Cuisine Universal") (the "SPAC Merger"), and (ii) concurrently with the SPAC merger, CUPS Sub Limited, a Cayman Islands exempted company and wholly owned subsidiary of Cuisine Universal, will be merged with and into Gaokai, resulting in Gaokai being a wholly owned subsidiary of Cuisine Universal (the "Business Combination" and the transactions in connection with the Business Combination collectively, the "Transaction"). Upon the closing of the Transaction, the combined company Cuisine Universal expects to be Nasdaq-listed under the ticker symbol "CUPS."

QSEA

QSEAU

Broadway Technology (Gaokai) Enters Merger Agreement With Quartzsea Acquisition Corp To Complete SPAC Business Combination; Combined Entity To Trade On Nasdaq As "CUPS" Under Cuisine Universal Structure

Press Releases

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

Comments

Cardiol Therapeutics

ニュース

最新ニュース Cardiol Therapeutics (NASDAQ:CRDL) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル